{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:43:37Z","timestamp":1793497417904,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["Study number 221602"],"award-info":[{"award-number":["Study number 221602"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03349-7","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T06:59:27Z","timestamp":1758783567000},"page":"5960-5977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Comparative Effectiveness Study in Patients with Asthma Initiating Fluticasone Furoate\/Vilanterol or Beclometasone Dipropionate\/Formoterol Fumarate in General Practice in England"],"prefix":"10.1007","volume":"42","author":[{"given":"Ashley","family":"Woodcock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Blakey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Hulme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Tritton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanchayita","family":"Sadhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunangshu","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8877-235X","authenticated-orcid":false,"given":"Manish","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"3349_CR1","unstructured":"Public Health England. Asthma: QOF prevalence (6+ yrs) 2024 [Available from: https:\/\/fingertips.phe.org.uk\/search\/Asthma]. Accessed 12 Jun 2025"},{"key":"3349_CR2","unstructured":"Global Asthma Network. Global Asthma Report 2022 [Available from: http:\/\/globalasthmareport.org\/resources\/Global_Asthma_Report_2022.pdf]. Accessed 12 Jun 2025."},{"key":"3349_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12890-017-0409-3","volume":"17","author":"RY Suruki","year":"2017","unstructured":"Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17:74\u201384.","journal-title":"BMC Pulm Med"},{"key":"3349_CR4","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2025 [Available from: https:\/\/ginasthma.org\/2025-gina-strategy-report\/]."},{"key":"3349_CR5","unstructured":"National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management 2024 [Available from: https:\/\/www.nice.org.uk\/guidance\/ng245\/chapter\/Recommendations#pharmacological-management-in-people-aged-12-and-over]. Accessed 12 Jun 2025."},{"key":"3349_CR6","unstructured":"British National Formulary. Beclometasone with formoterol. 2025 [Available from: https:\/\/bnf.nice.org.uk\/drugs\/beclometasone-with-formoterol\/]. Accessed 12 Jun 2025."},{"key":"3349_CR7","unstructured":"British National Formulary. Fluticasone with vilanterol. 2025 [Available from: https:\/\/bnf.nice.org.uk\/drugs\/fluticasone-with-vilanterol\/]. Accessed 12 Jun 2025."},{"key":"3349_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s12325-024-02823-y","volume":"41","author":"P Daley-Yates","year":"2024","unstructured":"Daley-Yates P, Aggarwal B, Plank M. Pharmacological basis of differences in dose response, dose equivalence, and duration of action of inhaled corticosteroids. Adv Ther. 2024;41:1995\u20132009.","journal-title":"Adv Ther"},{"issue":"1","key":"3349_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.25259\/ANAMS_150_2024","volume":"61","author":"R Garg","year":"2025","unstructured":"Garg R. Vilanterol vs formoterol in obstructive airway diseases: a comprehensive review of efficacy, safety, and clinical advantages in light of Global Initiative for Asthma 2024 and Global Initiative for Chronic Obstructive Lung Disease 2024 guidelines. Ann Natl Acad Med Sci (India). 2025;61(1):11\u20135.","journal-title":"Ann Natl Acad Med Sci (India)"},{"key":"3349_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12890-015-0150-8","volume":"15","author":"A Woodcock","year":"2015","unstructured":"Woodcock A, Bakerly ND, New JP, Gibson JM, Wu W, Vestbo J, Leather D. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. BMC Pulm Med. 2015;15:160\u20134.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"3349_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1513\/AnnalsATS.201410-459OC","volume":"12","author":"AC Wu","year":"2015","unstructured":"Wu AC, Butler MG, Li L, Fung V, Kharbanda EO, Larkin EK, et al. Primary adherence to controller medications for asthma is poor. Ann Am Thorac Soc. 2015;12(2):161\u20136.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"3349_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12931-024-03084-7","volume":"26","author":"HS Park","year":"2025","unstructured":"Park HS, Lee J, Kim H, Woo SD. Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS\/LABA combinations in asthma management. Respir Res. 2025;26(1):12\u201322.","journal-title":"Respir Res"},{"issue":"1","key":"3349_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/02770903.2019.1663429","volume":"58","author":"CM Averell","year":"2021","unstructured":"Averell CM, Stanford RH, Lalibert\u00e9 F, Wu JW, Germain G, Duh MS. Medication adherence in patients with asthma using once-daily versus twice-daily ICS\/LABAs. J Asthma. 2021;58(1):102\u201311.","journal-title":"J Asthma"},{"key":"3349_CR14","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/S0140-6736(17)32397-8","volume":"390","author":"A Woodcock","year":"2017","unstructured":"Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017;390:2247\u201355.","journal-title":"Lancet"},{"issue":"6","key":"3349_CR15","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1007\/s12325-020-01344-8","volume":"37","author":"M Parimi","year":"2020","unstructured":"Parimi M, Svedsater H, Ann Q, Gokhale M, Gray CM, Hinds D, et al. Persistence and adherence to ICS\/LABA drugs in UK patients with asthma: a retrospective new-user cohort study. Adv Ther. 2020;37(6):2916\u201331.","journal-title":"Adv Ther"},{"key":"3349_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40248-018-0131-x","volume":"13","author":"RW Dal Negro","year":"2018","unstructured":"Dal Negro RW, Bonadiman L, Turco P. Fluticasone furoate\/vilanterol 92\/22 \u03bcg once-a-day vs beclomethasone dipropionate\/formoterol 100\/6 \u03bcg B.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma. Multidiscip Respir Med. 2018;13:18\u201328.","journal-title":"Multidiscip Respir Med."},{"key":"3349_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053964","volume":"12","author":"A Sicras-Mainar","year":"2022","unstructured":"Sicras-Mainar A, G\u00f3mez Rodr\u00edguez B, Traseira-Lugilde S, Fern\u00e1ndez-S\u00e1nchez T, Velasco Garrido JL. Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study. BMJ Open. 2022;12: e053964.","journal-title":"BMJ Open"},{"issue":"5","key":"3349_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1056\/NEJM200008033430504","volume":"343","author":"S Suissa","year":"2000","unstructured":"Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332\u20136.","journal-title":"N Engl J Med"},{"key":"3349_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/JAA.S223093","volume":"12","author":"K Furuhashi","year":"2019","unstructured":"Furuhashi K, Fujisawa TA-O, Hashimoto D, Kamiya Y, Yasui H, Karayama M, et al. Once-daily fluticasone furoate\/vilanterol combination versus twice-daily budesonide\/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial. J Asthma Allergy. 2019;12:253\u201361.","journal-title":"J Asthma Allergy."},{"key":"3349_CR20","unstructured":"Clinical Practice Research Datalink. CPRD GOLD May 2022 dataset 2022 [Available from: https:\/\/www.cprd.com\/cprd-gold-may-2022-dataset]. Accessed 12 Jun 2025."},{"key":"3349_CR21","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/ije\/dyz034","volume":"48","author":"A Wolf","year":"2019","unstructured":"Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, Myles P. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48:1740\u20137.","journal-title":"Int J Epidemiol"},{"issue":"8","key":"3349_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017474","volume":"7","author":"F Nissen","year":"2017","unstructured":"Nissen F, Morales DR, Mullerova H, Smeeth L, Douglas IJ, Quint JK. Validation of asthma recording in the clinical practice research datalink (CPRD). BMJ Open. 2017;7(8): e017474.","journal-title":"BMJ Open"}],"updated-by":[{"DOI":"10.1007\/s12325-025-03407-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03349-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03349-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:03:59Z","timestamp":1763132639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03349-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3349"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03349-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update in supplement file.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-025-03407-0","URL":"https:\/\/doi.org\/10.1007\/s12325-025-03407-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ashley Woodcock has given lectures for Orion, and consulted for GSK and Orion. John Blakey reports grants or contracts from AstraZeneca, GSK and Novartis; consulting fees from Boehringer Ingelheim, Chiesi and GSK; payment or honoraria from AstraZeneca, Chiesi and GSK; support for attending meetings and\/or travel from AstraZeneca, Boehringer Ingelheim and GSK; receipt of medical writing support from GSK and Teva; payment to their institution for advisory work from Asthma Australia; and unpaid advisory work from Asthma WA. Arnaud Bourdin has received grants, personal fees, non-financial support and other support from Actelion, AstraZeneca, Boehringer Ingelheim and GSK; personal fees, non-financial support and other support from Chiesi, Novartis and Regeneron; personal fees and non-financial support from Teva; personal fees from Gilead; non-financial support and other support from Roche; and other support from Nuvaira. Giorgio Walter Canonica reports having received research grants as well as being a lecturer or having received advisory board fees from: A.Menarini, AstraZeneca, Celltrion, Chiesi, Faes, Firma, Genentech, GSK, Hal Allergy, Innovacaremd, Novartis, OmPharma, RedMaple, Sanofi\u2013Aventis, Sanofi\u2013Regeneron, Stallergenes\u2013Greer and Uriach Pharma. Christian Domingo declares having received financial aid for travel support and speakers\u2019 bureaus from ALK-Abello, Allergy Therapeutics, AstraZeneca, Chiesi, GSK, Hall Allergy, Inmunotek, A.Menarini Diagnostics, MSD, Novartis, Roxall, Sanofi and Stallergenes. Alexander Ford, Rosie Hulme and Theo Tritton are employees of Adelphi Real World, which received funding for this study from GSK. Ines Palomares, Arunangshu Biswas, Sanchayita Sadhu and Manish Verma are GSK employees; Ines Palomares, Arunangshu Biswas and Manish Verma hold financial equities in GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted according to GSK SOP52213 (Conducting Quality Control Review of Study Results generated using Existing Data in VEO and USVEO) and complied with all applicable laws regarding patient privacy. CPRD has NHS Health Research Authority (HRA) Research Ethics Committee (REC) approval to allow the collection and release of anonymised primary care data for observational research [NHS HRA REC reference number: 05\/MRE04\/87]. Each year, CPRD obtains Section\u00a0251 regulatory support through the HRA Confidentiality Advisory Group (CAG), to enable patient identifiers, without accompanying clinical data, to flow from CPRD contributing GP practices in England to NHS Digital, for the purposes of data linkage [CAG reference number: 21\/CAG\/0008]. The protocol for this research was approved by CPRD\u2019s Research Data Governance (RDG) Process (protocol number: 221602) and the approved protocol is available upon request. Linked pseudonymised data were provided for this study by CPRD. Data are  linked by NHS Digital, the statutory trusted third party for linking data, using identifiable data held only by NHS Digital. Select general practices consent to this process at a practice level with individual patients having the right to opt-out. This study is based in part on data from the CPRD obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the NHS as part of their care and support. The Office for National Statistics (ONS) was the provider of the ONS Data contained within the CPRD Data and maintains a Copyright\n                      \u00a9\n                      [2025], The Hospital Episode Statistics (HES) was the provider of HES-Admitted Patient Care and HES-Outpatient databases contained within the CPRD Data and maintain a Copyright\n                      \u00a9\n                      [2025] and Copyright\n                      \u00a9\n                      [2025] respectively. Linked data were re-used with the permission of The Health & Social Care Information Centre, all rights reserved. As this study used aggregate CPRD-HES data omitting patient identification, no patient contact or primary collection of data from human participants was required. The interpretation and conclusions contained in this study are those of the authors alone.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}